Correspondence 0001104659-26-067935 from Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc.
Date: May 29, 2026 · CIK: 0001279704 · Accession: 0001104659-26-067935
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296036
Letter
CELLECTAR BIOSCIENCES, INC.
100 Campus Drive
Florham Park, New Jersey 07932
May 29, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Cellectar Biosciences, Inc.
Registration Statement on Form S-1/A
Filed May 29, 2026
File No. 333-296036
Ladies and Gentlemen:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc., a Delaware corporation (the "Company"), hereby requests that the effective date of the Company's Registration Statement on Form S-1/A (Registration No. 333-296036), be accelerated so that the Registration Statement will become effective at 4:00 p.m. on June 1, 2026, or as soon as practicable thereafter.
The cooperation of the staff in meeting our request is very much appreciated. If you have any questions or comments, please contact Nick DeAngelis (214-969-3563 or ndeangelis@sidley.com). Thank you for your assistance with these matters.
Very
truly yours,
CELLECTAR
BIOSCIENCES, INC.
Show Raw Text
CORRESP 1 filename1.htm CELLECTAR BIOSCIENCES, INC. 100 Campus Drive Florham Park, New Jersey 07932 May 29, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Cellectar Biosciences, Inc. Registration Statement on Form S-1/A Filed May 29, 2026 File No. 333-296036 Ladies and Gentlemen: Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc., a Delaware corporation (the "Company"), hereby requests that the effective date of the Company's Registration Statement on Form S-1/A (Registration No. 333-296036), be accelerated so that the Registration Statement will become effective at 4:00 p.m. on June 1, 2026, or as soon as practicable thereafter. The cooperation of the staff in meeting our request is very much appreciated. If you have any questions or comments, please contact Nick DeAngelis (214-969-3563 or ndeangelis@sidley.com). Thank you for your assistance with these matters. Very truly yours, CELLECTAR BIOSCIENCES, INC. By: /s/ Chad J. Kolean Chad J. Kolean, Chief Financial Officer cc: James V. Caruso Asher M. Rubin Istvan A. Hajdu Nick DeAngelis